IVD Clinical Trials (In Vitro Diagnostic Studies)

An IVD clinical trial — formally a performance study in EU regulatory language, or an IVD investigation in the rare US cases where one requires an Investigational Device Exemption (IDE) — evaluates an in vitro diagnostic test’s ability to detect, measure, or characterize a condition, analyte, or biomarker using specimens taken from the human body, rather than administering a drug or activating a device inside a patient. Because the great majority of IVD studies analyze specimens that were already collected, or are collected through routine, minimal-risk procedures such as a standard blood draw or nasal swab, IVD trials follow a genuinely distinct regulatory pathway from both drug trials (the Investigational New Drug (IND) pathway) and therapeutic device trials (the Investigational Device Exemption pathway under 21 CFR Part 812). See the site’s IND vs. IDE comparison for how drug and therapeutic-device trials differ from each other; this entry covers where IVD studies sit relative to both.

US pathway: often exempt from the IDE requirement entirely

Under FDA regulation, IVDs are legally devices, so an IVD study is in scope of 21 CFR Part 812 by default — but Part 812 itself carves out a specific exemption for diagnostic devices at 21 CFR 812.2(c)(3). A diagnostic device study is exempt from nearly all of Part 812’s IDE requirements if, and only if, the testing:

• is noninvasive;
• does not require an invasive sampling procedure that presents significant risk;
• does not by design or intention introduce energy into a subject; and
• is not used as a diagnostic procedure without confirmation of the diagnosis by another, medically established diagnostic product or procedure.

A study meeting all four criteria is exempt from Part 812 in its entirety except for one provision, 21 CFR 812.119 (disqualification of a clinical investigator), and the sponsor must still comply with the investigational-use labeling requirement at 21 CFR 809.10(c). In practice, this exemption is why most IVD studies — testing residual or banked specimens, or specimens collected through a routine venipuncture or swab alongside standard-of-care testing — proceed without ever filing an IDE application, even though the same 21 CFR Part 812 that governs therapeutic device trials technically applies to IVDs as a device category. Any IVD study that will support an FDA marketing submission also remains subject to 21 CFR Part 50 (informed consent) and 21 CFR Part 56 (IRB oversight), exemption from Part 812 notwithstanding.

Not every IVD study qualifies for this exemption. An IVD study that involves an invasive specimen-collection procedure carrying more than minimal risk (for example, a research biopsy performed solely for the study), or that is used as a stand-alone diagnostic basis for a clinical management decision without confirmation by an established method, falls outside 812.2(c)(3) and is evaluated the same way a therapeutic device study is: through FDA’s significant risk (SR) / non-significant risk (NSR) determination, with an SR study requiring a full IDE application and IRB-approved NSR studies proceeding under abbreviated IDE requirements. Companion diagnostics — IVDs co-developed with a specific therapeutic to select which patients should receive it — are a common case where an IDE ends up required, because the diagnostic result directly drives an irreversible treatment decision within the same trial.

EU pathway: a separate regulation from therapeutic devices (IVDR, not MDR)

The EU draws the same line even more explicitly, through separate regulations rather than a single regulation with an internal exemption. Therapeutic and diagnostic-imaging devices are governed by the Medical Device Regulation (MDR, Regulation (EU) 2017/745), under which a human study is called a clinical investigation. In vitro diagnostics are governed by a wholly separate regulation, the In Vitro Diagnostic Regulation (IVDR, Regulation (EU) 2017/746), under which the equivalent human study is called a performance study — a study undertaken to establish or confirm a device’s analytical performance (does the assay measure the target analyte accurately and reproducibly) and/or its clinical performance (does the result correlate with the clinical condition or physiological state it claims to detect). See the site’s EU Clinical Trials Regulation and CTIS entry for the separate framework governing interventional drug trials in the EU, which is distinct from both MDR and IVDR.

Performance studies under IVDR follow good study practice as set out in the international standard ISO 20916, and their results feed a Performance Evaluation Report — the IVDR analogue of the Clinical Evaluation Report an MDR-regulated therapeutic device compiles. Not every IVD requires a dedicated performance study: where existing literature, equivalent-device data, or routine clinical data already demonstrate conformity with IVDR’s general safety and performance requirements, a manufacturer can rely on that evidence instead of running a new study — performance studies are generally reserved for novel markers, new intended uses, or claims not already supported by adequate existing evidence. Higher-risk IVD studies (interventional performance studies, or those involving specimens collected specifically and invasively for the study) require notified-body and, depending on classification and member-state rules, competent-authority notification or approval before starting, broadly analogous to how higher-risk MDR clinical investigations and FDA significant-risk IDE studies require prospective regulatory sign-off.

Why the distinction matters operationally

For a research administrator or regulatory professional scoping a study, correctly classifying it as an IVD study rather than a drug or therapeutic-device study up front determines which submission pathway, which regulation, and often which timeline applies — misclassifying an IDE-required companion-diagnostic study as exemption-qualified (or vice versa) is a preventable and consequential error. The practical test is what the study evaluates, not merely what materials it uses: a study that analyzes a specimen taken from the body to assess a diagnostic test’s performance is an IVD study; a study that administers a drug or activates a device inside the patient is not, even if it also involves drawing blood or running lab assays alongside the intervention.

Related CASRAI resources

See the IND vs. IDE comparison for how drug and therapeutic-device trial pathways differ from each other, the Investigational New Drug (IND) entry for the drug-trial pathway, the EU Clinical Trials Regulation and CTIS entry for the EU’s separate interventional-drug-trial framework, the FDA 510(k) premarket notification guide for how a device (including many IVDs) reaches market once study evidence is in hand, and the Clinical Research Administration pillar page.

References

• 21 CFR Part 812 (Investigational Device Exemptions), including § 812.2(c)(3) exemption criteria for diagnostic devices and § 812.119 (ecfr.gov)
• 21 CFR 809.10(c) (investigational-use labeling requirement for IVDs) (ecfr.gov)
• Regulation (EU) 2017/746, In Vitro Diagnostic Regulation (IVDR) (eur-lex.europa.eu)
• Regulation (EU) 2017/745, Medical Device Regulation (MDR), for comparison (eur-lex.europa.eu)
• ISO 20916:2019, In vitro diagnostic medical devices — Clinical performance studies using specimens from human subjects (iso.org)
• FDA, “In Vitro Diagnostic (IVD) Device Studies — Frequently Asked Questions,” guidance for industry and FDA staff (fda.gov)